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Abstract: The Industrial Pharmacy Lab (IPL) was founded in 2001 and has been awarded the NETS Award and NETS 
Special Award of the Gebert Rüf Foundation, Basel in 2004. The IPL is a turning platform between the university 
and the pharmaceutical industry at the Pharma Hub Basel with the focus on research in powder technology, dosage 
form design and scale-up. The IPL works with industrial-sized equipment and applies new and state-of-the-art 
technologies to the development of robust formulations. In the present article the research fields granulation pro-
cess control, formulation of low water soluble drugs, modified release, and impact of the filling process on protein 
solutions are introduced and critical parameters, sources of variability, and scale-up problems are identified in order 
to suggest and provide a rational and optimal formulation and process for pharmaceutical dosage form design.
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The mission of the IPL is to focus on 
research in powder technology, dosage 
form design and scale-up. This research is 
very close to today’s needs of the pharma-
ceutical industry; looking for robust for-
mulations and process technologies, which 
should shorten the development time and 
increase the product quality. A close coop-
eration with the pharmaceutical industry is 
a prerequisite to be able to do studies in the 
area of scale-up aiming to understand and 
control pharmaceutical processes, which is 
in agreement with the basic tenet of ‘qual-
ity by design’ of the FDA’s PAT (Process 
Analytical Technology) initiative.
Over 80% of the active drugs that are 
formulated to produce systemic effects in 
patients are marketed as solid dosage forms, 
due to the great acceptance of patients to 
take tablets. Furthermore, more than 40% 
of newly discovered drugs are poorly water 
soluble, and there is no universal formula-
tion technique for any sparingly water-solu-
ble drug. Therefore, the pharmaceutical in-
dustry is investing vast amounts of money 
in research and development of this specific 
area. However, the severe problem of the 
pharmaceutical industry is to increase pro-
ductivity and creativity at the same time, 
and therefore they seek collaborations with 
universities. Based on this mutual interest 
between university and pharmaceutical 
industry the Industrial Pharmacy Lab was 
founded as a turning platform between the 
two sides.
The IPL applies new and state-of-the-
art technologies and equipment to the de-
velopment of robust formulations leading 
to reliable manufacturing processes for 
high volume production. The IPL works 
with industrial-sized equipment such as a 
compaction simulator (sponsored by Pfiz-
er, Freiburg), different types of tableting 
machines (sponsored by Korsch, Berlin), 
equipment for manufacturing granules and 
pellets (sponsored by Glatt, Binzen), a cap-
sule filling machine (sponsored by Pfizer, 
Freiburg), a roller compactor (sponsored 
by Fitzpatrick, Sint-Niklaas, Belgium) and 
a sterile ampoule filling line (sponsored by 
Novartis, Basel).
2. Research Fields
Tablets are complex systems and the 
behaviour of disordered particulates under 
pressure is still far from being well under-
stood, especially with high-speed compres-
sion cycles similar to presses used in indus-
try. Manufacturing problems of tablets are 
usually discovered towards the end of the 
development process when compression 
runs are studied for the first time. The use 
of a compaction simulator in the early stage 
of development is a significant benefit for 
the product development process.
In the pharmaceutical process of tablet 
production, moist agglomeration is com-
monly applied to powder mixtures in order 
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to improve powder characteristics such as 
flow and compressibility. The desired prop-
erties of the granules are controlled by a 
combination of formulation design (choos-
ing the starting material and liquid accord-
ing to its properties) and process design 
(choosing the type of granulator and the op-
erating parameters). Changing the formu-
lation and/or the process itself is followed 
by a high number of experiments based on 
trial and error. Furthermore, a change in the 
quality of granules can have an influence on 
the compression runs, especially with high 
speed cycles and therefore on the properties 
of the final tablet.
The aim of the research group working in 
the Industrial Pharmacy Lab is to understand 
and, in a second step, to control pharmaceu-
tical processes in the field of dosage form 
design in order to develop robust formula-
tions and to increase the product quality. It 
is essential that the ‘art of formulation’ is 
converted into science, taking into account 
percolation theory and the laws of physi-
cal pharmacy. This is in agreement with the 
science-driven PAT initiative, which is an 
effort to facilitate the introduction of new 
technologies into the pharmaceutical in-
dustry. The vision is to investigate, design, 
and develop processes that can consistently 
ensure a predefined quality at the end of the 
manufacturing process.
In the present research overview of the 
IPL, tools for robust dosage form design are 
introduced in the following areas:
–  Granulation Process Control (2.1.)
–  Formulation of Low Water-soluble 
Drugs (2.2.)
–  Modified Release (2.3.)
–  Impact of the Filling Process on Protein 
Solutions (2.4.)
In all the four areas, it is important to 
identify critical parameters, non-robust for-
mulations, sources of variability and scale-
up problems in order to suggest and pro-
vide a rational and optimal formulation and 
process for pharmaceutical dosage form 
design.
2.1. Granulation Process Control
The research work in the area of granu-
lation process control gave valuable insight 
into process and formulation design. Power 
consumption, temperature recording, and 
tensile strength measurements during the 
granulation process led to an in-process 
control device which records and analyses 
the power consumption profile taking into 
account the properties of the starting mate-
rial, such as particle size, surface, solubil-
ity, and wettability. Applying the theory of 
percolation, three percolation thresholds 
were obtained during the granulation pro-
cess with mannitol due to a superposition of 
bond and site percolation effects. In robust 
formulation design it is important to deter-
mine the percolation thresholds for each 
formulation in order to avoid variations in 
granule quality. 
The compression behaviour of pharma-
ceutical substances and the final property of 
the tablet can be significantly influenced by 
the properties of the starting material and 
the granulate. In order to maintain the gran-
ulate quality, an in-process control device 
was applied to various tablet formulations. 
The turning point of the power consump-
tion profile was introduced as the parameter 
for the cohesiveness of the starting material 
and used for optimal end-point detection 
at an early stage. The influence of chang-
ing the granulating liquid on the power 
consumption profile could be predicted by 
calculating the ratios of the surface tension 
of the granulating liquids. Furthermore, 
tensile strength measurements proved that 
the developed device, measuring the power 
consumption of the granulator, is an alter-
native to determining the cohesion of pow-
der particles [1–4]. 
Temperature recording was also intro-
duced as an efficient in-process control. Fur-
thermore, the ratio of power consumption 
and temperature recording (TPR) was intro-
duced as a signature of formulation design. 
The influence of changing the formulation 
can be predicted by considering particle size, 
particle surface, water absorption capacity 
and solubility of the starting material. The 
TPR-factor was determined to be dependent 
on formulation design, and not on process 
design, such as the filling level of the mixer. 
The filling volume-specific power consump-
tion was also discovered to be independent 
of the relative filling level. This is an impor-
tant result for granulation process scale-up, 
and allows the estimation of the power con-
sumption of larger scales before the process 
is started. The results of the presented work 
[5][6] have given valuable information about 
the granulation process and are currently 
used to develop an artificial neural network 
for in-process granulation control.
The first results were obtained by ap-
plying Kohonen networks [7] and self-
organized maps to determine the critical 
granulation process steps; and furthermore, 
to avoid them. Application of different 
techniques for power consumption signal 
analysis is currently being compared and 
optimized for the in-process device in co-
operation with the Mendeleyev University, 
Moscow. 
2.2. Formulation of Low Water-solu-
ble Drugs
Based on the excellent results of the re-
search group of Prof. Dr. Hans Leuenberger 
in powder technology, the research topic 
is extended to compaction simulation. A 
compaction simulator – PressterTM (MCC) 
– was sponsored by Pfizer (Freiburg, Ger-
many) and allows multi station rotary tab-
let presses to be simulated using only a 
minimal amount of tableting material, and 
to avoid problems towards the end of the 
development process. Two examples of low 
water-soluble drugs, mefenamic acid and 
carbamazepine, belonging to Class II of the 
bioclassification system, were selected for 
investigations. In fact, more than 40% of 
the discovered drugs fall into these catego-
ries and additionally (i.e. in the UK) 41% 
count as failures in new drug development 
due to biopharmaceutical properties, solu-
bility being one of them.
2.2.1. Mefenamic Acid (MA)
In order to increase the specific surface 
of a low water-soluble drug, it is important 
that the tablet shows an optimal and fast 
disintegration. 
Investigations were performed to opti-
mize the loading volume of mefenamic acid 
for granules and tablet formulations. The 
investigation ranged from the placebo for-
mulation up to the loading volume of 75% 
(v/v) MA. Characteristics of granules and 
tablets produced by the fluidized bed gran-
ulator and compaction simulator, respec-
tively, were evaluated in order to suggest 
formulation rules for the use of mefenamic 
acid in solid dosage forms.
The fastest disintegration time was ob-
tained with 50% mefenamic acid (Fig. 1) 
even though mefenamic acid shows low 
water solubility and wettability. With lower 
and higher MA content the disintegration 
time increased.
It can be assumed that the disintegrant 
particles, such as maize starch, are in close 
contact with the network of pores which ex-
tends throughout the whole tablet. At a con-
centration lower than the critical amount of 
disintegrant, the individual particles do not 
cover all pore sites of the porous network. 
As the drug substance is hydrophobic, the 
hydrophilic particles facilitate the water 
uptake due to hydrophilized pores. For a 
concentration higher than the percolation 
threshold, the water uptake is reduced due 
to the swelling properties of the disinte-
grant [8–11]. 
2.2.2. Carbamazepine
Carbamazepine (CBZ) exhibits at least 
four polymorphic forms and a dihydrate. 
CBZ polymorphs have different crystal 
structures and exhibit different melting 
points, chemical reactivity, solubility, and 
compactibility, all of which can contribute 
to differences in bioavailability. The pure 
active substance can contain a mixture of 
polymorphs and crystal modifications as 
well as amorphous material. This vari-
ation can lead to an alteration in the dis-
solution profile during storage due to the 
transformation from one polymorph to the 
other. Therefore, there is a need to define 
adequate parameters and properties which 
must be monitored and controlled in order 
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to maintain the shelf-life stability of CBZ 
solid dosage forms. The aim of the study 
was to investigate the influence of variabil-
ity of commercially available CBZ from 
different manufacturers on the intrinsic dis-
solution behaviour and solubility in order to 
recommend a strategy to maintain product 
quality by monitoring critical parameters of 
the bulk drug.
The results obtained with differential 
scanning calorimetry (DSC) confirmed that 
all CBZ samples belonged to polymorphic 
form III (Table 1). The melting point of form 
I of all commercial samples was determined 
as ca. 192 °C, and was in agreement with the 
result obtained for CBZ USP standard. 
The solubility of CBZ samples at equi-
librium and the intrinsic dissolution data 
are shown in Table 2.
Anhydrous CBZ (CBZ P, Pc, A, B1, B2) 
was assumed to undergo a phase transition 
into the dihydrate form (CBZ D) indicated 
by the change of slope in the dissolution 
profile. Based on this result, the intrinsic 
dissolution rates were calculated from the 
initial slope of each form after 20 min (Fig. 
2). Although all commercially analyzed 
samples of CBZ showed the same polymor-
phic form, solubility and intrinsic dissolu-
tion rates were found to vary among them 
and to be significantly lower compared to 
literature data. It is suggested that the in-
trinsic dissolution kinetics were changing 
during experiments due to the transition of 
the anhydrous form of CBZ [12] to the di-
hydrate.
All these variations can be attributed to 
various manufacturing processes and are 
most likely to result from different drying 
and/or grinding regimes in the final stage 
of the manufacture.
The dihydrate dissolution profile 
showed a change of slope as well, which 
is not in agreement with literature data. A 
possible reason is the impurity of the dehy-
drate itself, and thus further investigations 
are needed. 
2.3. Modified Release
Modified release dosage forms optimize 
the therapeutic efficiency of drug treatment 
by minimizing drug fluctuations in the sys-
temic circulation by extending the duration 
of action. Thus dose frequency can be re-
duced, resulting in an improvement of dose 
discipline for the patients. 
Modified release from matrix systems 
prepared from insoluble polymer or lipid 
matrices is determined by the pore struc-
ture of the system. Drug particles dispersed 
in the insoluble matrix become available as 
the solvent enters the matrix and dissolves 
the particles. In the work of Bonny [13–15] 
fractal dimensions were used to describe ir-
regular surfaces and pore structures of matrix 
systems consisting of ethylcellulose or hy-
drogenated castor oil and caffeine. The pore 
structure remaining after different amounts 
of drug were released was described by the 
volume and surface fractal dimension. The 
volume fractal dimension DV turned out to 
be a useful parameter to characterize the 
pore structure generated by the dissolution 
of the drug. The latter was influenced by 
the grain size of the incorporated drug and 
decreased in an approximately linear way 
with increasing leaching time of the corre-
sponding matrix. The preparation of such 
matrix systems is very simple and inexpen-
sive, and can be performed by direct com-
pression of the mixture or by compression 
after granulation. Applying the concepts of 
percolation theory [16] to the diffusion of 
a drug out of a matrix, it was demonstrated 














Fig. 1. Disintegration of tablets with increasing loading amount of MA
Table 1. DSC results of CBZ samples
Solid–solid transformation 
III‡ I [°C]
Melting point of 
form I [°C]
Enthalpy [J/g]
CBZ USP 176.57 191.88 107.32
CBZ Da 60.54–89.05 191.92 92.87
CBZ P 184.96 192.38 106.31
CBZ A 174.10 191.79 107.13
CBZ B1 176.52 192.96 108.89
CBZ B2 177.16 192.91 106.98
adehydratation






CBZ D 23.6 253.6
CBZ P 18.0 207.3
CBZ Pc 20.4 237.5
CBZ A 53.9 430.4
CBZ B1 18.5 275.1

















Fig. 2. Dissolution profile during the intrinsic dissolution 
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that in a binary system consisting of the 
drug and the matrix-forming excipient, two 
percolation thresholds can be determined. 
The lower percolation threshold pc1 corre-
sponds to a critical porosity εc of the matrix, 
and was determined to be 0.32 for ethylcel-
luose matrices containing caffeine as drug 
particles. The upper percolation threshold 
(pc2), however, represents the critical vol-
ume fraction of matrix substance which is 
required to ensure the integrity of the ma-
trix during drug release, and was found to 
be smaller than 0.29 [15]. 
Polysaccharides are widely used in 
pharmaceutical formulation, and in several 
cases play a fundamental role in modified 
release control. A novel network-forming 
starch was used to prepare matrix systems 
with caffeine, and investigations were per-
formed on its future use in controlled re-
lease systems.
Matrix systems were prepared by extru-
sion with novel starch film containing caf-
feine in the concentration range of 5–50%. 
Matrix tablets were prepared by mixing 
ground starch film with caffeine in respec-
tive amounts (5 to 50%) and pressed into 
tablets. It was shown that the caffeine re-
lease profile followed Higuchi’s square root 
of time law for all the starch disks and tab-
lets, and was in the range of ethylcellulose 
matrix systems.
The caffeine release profile was largely 
independent of drug loading, thickness of 
the delivery system and presence of amy-
lase in the dissolution media, however it de-
pended on the network density of prepared 
starch disks. Since the latter are made by 
simply adding different amounts of drug, 
starch and short-chain amylose, one can 
adjust the release rate for a given drug load-
ing [17].
2.4. Impact of the Filling Process on 
Protein Solutions
During production, proteins are exposed 
to various stresses which can cause protein 
denaturation and inactivation. The objective 
of the present study was to investigate the 
effect of shear forces which can occur dur-
ing filling operations of pharmaceutical so-
lutions with dosing equipment. Such shear 
forces could have a negative influence on 
shear sensitive substances and may lower 
the quality of the final product. In the first 
part of this work the influence of various 
parameters during the filling operation such 
as filling speed, dosing volume and size of 
pumps was examined using a model pro-
tein solution. Furthermore, the influence of 
rotary piston pumps and peristaltic pumps 
was compared. In the second part, excipi-
ents were tested on their ability to protect 
the model protein against shear-induced 
damage. Photon correlation spectroscopy 
(PCS) and size exclusion chromatography 
were used to determine the z-average mean 
and the size distribution of the model pro-
tein before and after shearing, as a method 
to evaluate the degree of denaturation and 
aggregation. It was found that protein ag-
gregation was induced by rotary piston 
pumps and not by peristaltic pumps. The 
smaller the size of the rotary piston pumps 
the more protein aggregation occurred. The 
filling speed had a minor influence, and no 
protective effect could be seen by adding 
excipients [18]. 
3. Future Perspectives
New projects are currently running 
on the topic of ‘Controlled release tablets 
containing theophylline prepared by us-
ing an instrumented roller compactor’ and 
‘Stabilisation of the glucose blood level in 
diabetics using network-forming starch for-
mulations’. 
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